Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Arena Pharmaceuticals Inc. (ARNA): What to Expect from Earnings

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gets its turn in the earnings parade Thursday when it releases its quarterly report after the closing bell. The company, which has been in the news for the last couple months since receiving FDA approval for its weight-loss drug, Belviq, has come up a bit short of expectations over the past year. However, the stock has made a nice run over the last three months, so it will be interesting to see if the numbers live up to the stock. Here is an inside look at what may be expected from the report.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Over a three-month period from May 9 to August 8 of this year, the stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose more than 110 percent, from $3.42 a share to $7.30 a share. From June 7 to June 21, the stock gained 81 percent of its value when the price rose for 11 straight trading days. After that, however, the stock lost 15 percent of its value over six straight losing sessions from July 13 to July 20.

The average estimates among analysts calls for a net EPS loss of 8 cents, which is an improvement from a minus-16 cent EPS loss in the same quarter of 2011. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has missed quarterly EPS estimates in each of the last three quarters. On the revenue side, analysts are expecting to see about $7.4 million on the report, which would be a more than two-fold increase from the year-ago quarter and would end two straight quarter of revenue declines. The company reported $2.2 million in revenue in the first quarter of 2012 and $3.9 million in the fourth quarter of 2011.  The company lists an asset-to-liability ratio of more than 7.5, so the company’s overall financial health seems solid.

It is possible that Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will discuss its marketing and sales plans for Belviq at its conference call later Thursday, though the drug is not expected to hit the market until the first quarter of 2013.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!